Sucampo Pharmaceuticals — Investor Presentation (June 2014)
8 slides from Sucampo Pharmaceuticals's investor presentation, Jun 5, 2014
Slide 1: Clinical Focus and Stage of Clinical Development
CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL | PHASE 1 joprostone Isopropyl Retinitis F | PO lon Channel Activator Lumbar Spinal Stenosis aiid L_ EEE HICOMPLETED MIPROJECTED START BIONGOING e *Co-developing with R-Tech Ueno, Ltd. é SUCAMPO 2 he Science of Innovation
Slide 2: Lubiprostone Clinical Development
Lubiprostone Clinical‘Development 4 constipation functional for children end adolescents aged 6 - 17 years with PFC y ‘See Reference 4; 5 (Photo) 2014 ‘Abdominal radiograph of constipated chil showing P ‘Sool troughout he colon noe Formulation Based on f g ee funding 100% of the cost: $sucaMpo ® ‘Th
Slide 3: Unoprostone Isopropyl for Retinal Disease
Unoprostone Isopropylfor Retinal_Disease™ Retinitis Pigmentosa (RP) Prevalence: ~1 H from RP. available® 3 i R-Tech Ueno, Ltd + Interim 1 yr RPin U.S. & E.U. . p E.U. to $ sucAMPO iH ‘The Science of Innovation ‘See Reference 6,7 (Photo)
Slide 4: Trading Symbol and Corporate Headquarters
| Trading Symbol Corporate Headquarters to s ck Price Shares Outstanding (05-3 0-14), 52-Week Range 0-14) y average) apitalization (05-30-14) S AMITIZA U. Financial Guidance | 2014 Guidance ~ Net Income | $3M - $5M, or $0.06 - $0.11 (EPS) § sucAMPO ‘8 ‘The Science of innovation
Slide 5: Upcoming Events
Upcoming Events Commercial Clinical spinal stenosis Financial Q2 2014 Earnings call August 2014 Corporate Corporate Strategy Update Q3 2014 $ SUCAMPO 8 The Science of innovation
Slide 6: Key Facts & Financial Highlights
Key Facts & Financial Highlights Key Facts Financial Highlights for Q4 2014 $52.2M 8 of k) (1 class 1on stoc! 212,533 Market Capitalization $323.2M 4) (05-30-14) Enterprise Value $270.4M "AMITIZA U.S. Net Sales (05-30-14) ( ) (as reported by Takeda for | 575 yy royalty calculation urposes): $ sucAMP
Slide 7: Sucampo Prostone Pipeline Key Highlights
Sucampo Prostone Pipeline Key-Highlights Cobiprostone lon Channel Activators for Oral Mucositis for Lumbar Spinal Stenosis Lumbar Spinal Stenosis (LSS) age® Degenerative change in lumbar spine; unmet medical need with limited treatment options globally Top-tine results of P2a, double-blind, placebo-
Slide 8: References
References IMs Smart View, NPA Report, client Factored Numbers. Internal Re ssearch Fingertip Formulary (NOV 2013) ‘Sucampe data on file Clearview Analysis 2008 National Cancer Institute SEER Database (2012) ¢ ? SUCAMPO ey ‘The Science of Innovation
Sucampo Pharmaceuticals — Investor Presentation (June 2014) on 6ix